Comparison of Pharmacokinetics of Lanoteplase and Alteplase During Acute Myocardial Infarction
作者:
John B. Kostis,
Randy C. Dockens,
Udho Thadani,
Vasnath Bethala,
Carl Pepine,
Wayne Leimbach,
Nimish Vachharajani,
Ralph H. Raymond,
Bruce C. Stouffer,
Lee K. Tay,
Wen Chyi Shyu,
Wei-chi Liao,
期刊:
Clinical Pharmacokinetics
(ADIS Available online 2002)
卷期:
Volume 41,
issue 6
页码: 445-452
ISSN:0312-5963
年代: 2002
出版商: ADIS
关键词: Alteplase, pharmacokinetics;Lanoteplase, pharmacokinetics;Plasminogen activators, pharmacokinetics;Research and development
数据来源: ADIS
摘要:
ObjectiveLanoteplase is a rationally designed variant of tissue plasminogen activator. The aim of this study was to examine the pharmacokinetics and functional activity of a single intravenous bolus dose of lanoteplase with those of a bolus plus two-step infusion of alteplase.DesignSeven-centre substudy of the InTIME-I angiographic trial in patients presenting within 6 hours of onset of suspected acute myocardial infarction.Patients and ParticipantsA total of 31 patients (28 males, 3 females) enrolled in this substudy [mean age 59 (range 26 to 76) years].MethodsTwenty-three patients randomised to lanoteplase received single bolus doses of 15 kU/kg (n = 5), 30 kU/kg (n = 3), 60 kU/kg (n = 9), or 120 kU/kg (n = 6). Eight patients received alteplase ≤100mg as a bolus followed by a two-stage 90 min infusion. Blood samples were analysed for antigen concentration and plasminogen activator (PA) activity.ResultsThe distribution plasma half-life of approximately 35 min for lanoteplase was at least five times longer than that of alteplase. Lanoteplase plasma clearance averaged 3 L/h (50 ml/min), whereas the mean plasma clearance of approximately 24 L/h (400 ml/min) for alteplase approaches hepatic blood flow following acute myocardial infarction. PA activity after lanoteplase 120 kU/kg remained for 6 hours, compared with less than 4 hours after alteplase 100mg.ConclusionsThe longer antigen and activity half-lives, slower clearance and less complicated administration of lanoteplase compared with alteplase suggest that it may offer advantages for use as a single intravenous bolus to achieve reperfusion after myocardial infarction.
点击下载:
PDF
(259KB)
返 回